Source - LSE Regulatory
RNS Number : 6529O
Renishaw PLC
02 February 2023
 

Renishaw plc                                                              

 

2 February 2023

 

Interim report 2023 - for the six months ended 31 December 2022

 

Highlights

 

 

Good revenue growth from strategic priorities offsets weaker demand, as expected, from the semiconductor and electronics sectors. Continued investment for longer-term growth.

 

 

 

 

6 months to

31 December

2022

6 months to

31 December

2021

Change %

 


 



Revenue (£m)

347.7

325.2

+7


 



Adjusted1 profit before tax (£m)

73.5

84.2

-13


 



Adjusted1 earnings per share (pence)

83.4

97.2

-14


 



Dividend per share (pence) 

16.8

16.0

+5


 



Statutory profit before tax (£m)

77.8

81.5

-5


 



Statutory earnings per share (pence)

88.1

94.2

-6

 

 

·      Revenue of £347.7m (H1 FY2022 £325.2m):

•       Record revenue for a half year, 7% above last year (1% growth at constant exchange rates)

•       Strong growth in sales of multi-laser additive manufacturing (AM) systems, 5-axis co-ordinate measuring machine (CMM) inspection systems and laser encoders

•       Weaker demand, as expected, for optical encoders from semiconductor and consumer electronics sectors, including customers reducing stock levels due to improved supply chain lead times

·      Adjusted1 profit before tax of £73.5m (H1 FY2022 £84.2m):

•       Representing 21% of revenue (26% last year)

•       Stable gross margin before engineering costs

•       Targeted investments in headcount and pay for long-term growth

·      Statutory profit before tax of £77.8m (H1 FY2022: £81.5m).

·      Strong balance sheet with net cash and bank deposit balances of £211.5m, compared with £253.2m at 30 June 2022, with the £41.2m final dividend for FY2022 paid in H1.

·      Interim dividend of 16.8p per share.

William Lee, Chief Executive, commented:

 

"I am pleased to report record revenue in a period of expected lower demand from the semiconductor and electronics sectors. We have made good progress in our strategy; gaining market share, introducing new products into close-adjacent markets and taking advantage of long-term growth opportunities in additive manufacturing, shop-floor measurement, materials research and semiconductor manufacturing. We continue to invest in our people, product development and infrastructure to deliver sustainable, long-term growth."

 

1 Note 12, 'Alternative performance measures', defines how adjusted profit before tax and adjusted earnings per share are calculated.

 

 

About Renishaw

 

We are a world leading supplier of measuring systems and production systems. Our products give high accuracy and precision, gathering data to provide customers and end users with traceability and confidence in what they're making. This technology also helps our customers to innovate their products and processes. We are a global business, with customer-facing locations across our three sales regions; the Americas, EMEA, and APAC. Most of our R&D work takes place in the UK, with our largest manufacturing sites located in the UK, Ireland and India.

 

Results presentation and live Q&A session today

 

See below a video presentation of these results, presented by William Lee, Chief Executive, and Allen Roberts, Group Finance Director. There will be a live audio-only question and answer session with William and Allen at 10:30 GMT today. Details of how to register for and access this webcast are available at the following link:

https://www.renishaw.com/en/register-for-the-2023-interim-results-qa-webcast--47761

 

Questions can be submitted in advance of the webcast either through the webcast platform or to communications@renishaw.com (if sending by email, please submit by 10:00 GMT).

 

Enquiries: communications@renishaw.com 



 

 


 

Overview for the six months ended 31 December 2022

 

Revenue

Revenue for the six months ended 31 December 2022 was £347.7m, an increase of 7% (1% increase at constant exchange rates) compared with £325.2m for the corresponding period last year. We achieved revenue growth of 21% (8% at constant exchange rates) in the Americas, 7% (4% at constant exchange rates) in EMEA and 1% (-4% at constant exchange rates) in APAC. There was growth for both our Manufacturing technologies, and Analytical instruments and medical devices segments, with strong growth in sales of multi-laser additive manufacturing (AM) systems, machine calibration systems, laser encoder systems and REVO® 5-axis co-ordinate measuring machine (CMM) inspection systems. Demand from the semiconductor and electronics sectors was weaker, resulting in a reduction in sales of our optical encoder products.

 

 

 

6 months to

31 December

2022

6 months to

31 December

2021


Change %

Constant fx1 change %

Group revenue

£347.7m

£325.2m

+7

+1

Comprising:





   APAC

£161.7m

£160.6m

+1

-4

   Americas

£83.6m

£69.1m

+21

+8

   EMEA

£102.4m

£95.5m

+7

+4

 

 

Operating costs

Our gross margin (excluding engineering costs) for the period was 64% of revenue, which is similar to the previous year. An increase in manufacturing costs, primarily arising from pay rises for our employees, has been offset by a favourable currency effect on revenue and increases in our sales prices.

 

Group headcount has increased by 53 since the end of June and was 5,150 at the end of December 2022. This increase includes continued investment in our early careers programmes (mostly for research and development) and in our global sales and support teams. Labour costs (excluding bonuses) were £133.4m in this period compared to £115.1m last year, with the average headcount in the first half-year being 5,166 (H1 FY2022: 4,824). The increase also reflects the pay reviews we have carried out across our business over the last 14 months, helping to improve employee retention. Our pay benchmarking will now be undertaken around December each year, with the December 2022 review resulting in around £4m of additional annual cost.

 

With pandemic related restrictions now largely lifted, we have increased our investment in customer facing activities, resulting in higher travel and exhibitions costs compared to last year.

 

We remain committed to our long-term strategy of developing innovative and patented products to create strong market positions. During the first six months of this year, our investment in engineering, including research and development, increased by 22% to £46.1m. Since June, we have launched new products including the CENTRUM™ metal rotary scale disc system for our ATOM DX™ encoder series, the ACS-1 system that brings improved accuracy and speed to the calibration of machine tool probes and the new inLux™ SEM Raman interface for our spectroscopy line.

 

Profit and tax

Adjusted profit before tax1 for the period was £73.5m (21% of revenue) compared with £84.2m (26% of revenue) last year. Statutory profit before tax for the period was £77.8m, compared with £81.5m last year, which includes a £4.4m fair value gain (H1 FY2022: £2.9m loss) on financial instruments not effective for hedge accounting and not included in adjusted profit before tax. No forward contracts have been designated as ineffective since FY2020.

 

Financial income for the period was £5.0m compared with £0.4m last year, and includes a £2.3m increase in interest on bank deposits.

 

The income tax expense in the Consolidated income statement has been estimated at a rate of 17.7% (H1 FY2022: 15.9%) and is based on management's best estimate of the full year effective tax rates by geographical unit applied to half-year profits. This is comparable with the 17.3% achieved in FY2022 and includes an increase in the UK corporation tax rate for the year to 20.5% from 19.0%, which is largely offset by a forecast increase in the UK patent box benefit.

 

Adjusted earnings per share were 83.4p, compared with 97.2p last year. Statutory earnings per share were 88.1p, compared with 94.2p last year.

 

Manufacturing technologies

Revenue for this segment, which comprises our Industrial Metrology, Position Measurement and Additive Manufacturing businesses, was £330.9m for the first six months, compared with £308.7m last year. We achieved strong growth in the Americas and good growth in EMEA, with reduced revenue in our APAC region (at constant exchange rates) mainly due to lower sales of optical encoders to the semiconductor and electronics market. Adjusted operating profit was £66.8m, compared with £81.3m for the comparable period last year. As already noted there was strong growth for our RenAM 500Q multi-laser AM system where its productivity and ability to produce high quality parts is leading to repeat business from customers in sectors as diverse as consumer electronics, healthcare, aerospace, defence and tooling. There was also strong growth for our CMM inspection systems, based on the REVO® 5-axis system, which is meeting customer demands for multi-sensor metrology to provide comprehensive inspection and process feedback from a single measurement platform. Our calibration business also had strong growth compared to the same period last year as machine builders focus on the accuracy and reliability of ever more complex machinery. Weaker demand from our semiconductor customers due to reducing their stock levels and market uncertainty, led to reduced sales of our optical encoder products. However, demand for our high accuracy laser encoders for front-end semiconductor manufacturing processes was very strong. Global forecasts for the construction of semiconductor fabrication plants, driven by new technology, geopolitical considerations and supply chain security, remain positive and we are optimistic about a mid-term recovery in sales to this important sector. 

 

Analytical instruments and medical devices

Revenue from this segment for the first six months was £16.8m, compared with £16.5m last year. There was strong growth in both APAC and Americas regions, offset by significantly weaker demand from EMEA. The adjusted operating profit was £0.1m in the first half of this year compared with £1.6m for the comparable period last year. Revenue for our spectroscopy products was flat but we are seeing growth in the order book and strong demand in H1 for our newer products - the Virsa™ analyser, a portable system that allows sample analysis outside of a laboratory, and the recently launched inLux™ SEM Raman interface which allows simultaneous Raman and scanning electron microscope imaging. Our neurological business is continuing to progress opportunities with pharmaceutical companies to use our drug delivery technology for clinical trials.

 

Balance sheet

Net cash and bank deposit balances at 31 December 2022 were £211.5m, compared with £253.2m at 30 June 2022, primarily reflecting the cash generated from operating profit of £81.2m, offset by the working capital movement of £40.6m, capital expenditure of £20.2m, tax payments of £16.9m and the final dividend payment of £41.2m in respect of FY2022.

 

Inventory balances have increased by £17.3m since 30 June 2022, mainly reflecting targeted increases in components and sub-assemblies for our optical encoder products.  Trade receivables have decreased by £4.4m in the same period, with receivables days remaining consistent with June levels and no significant movement in expected credit losses. Trade and other payables have reduced by £19.6m since June, reflecting lower purchasing activity in the second quarter and payment of bonuses accrued at June.

 

We invested £20.2m (H1 FY2022: £12.2m) in capital expenditure during the first six months of this financial year, which includes production plant and equipment and £7.8m for the ongoing development of our production facility in Miskin, Wales.

 

Dividend

The Board has approved an interim dividend of 16.8 pence net per share (FY2022: 16.0p), relecting the Board's confidence in the medium term growth prospects of the business, which will be paid on 11 April 2023 to shareholders on the register on 10 March 2023.

 

Principal risks and uncertainties

The Board has considered the risks and uncertainties which could have a material effect on the Group's performance and position. While there is heightened uncertainty arising from geopolitical matters and trade tensions, the overall impact and likelihood of our principal risks is not considered to have changed significantly. This conclusion also reflects the mitigation undertaken by the Group in response to these risks. The principal risks and uncertainties set out on pages 39 to 49 of the 2022 Annual Report therefore remain relevant.

 

COVID-19 update

We continue to monitor the impact of COVID-19 on our people and business. The recent easing of restrictions in China led to a surge in COVID cases and whilst this is causing some short-term disruption to our customers' operations this is expected to dissipate in the next few months. The removal of travel restrictions in China is enabling us to better serve our customer base from across our extensive local office network. We continue to make better use of digital technology to work with each other, our customers and our suppliers, meaning we can work in a more sustainable way by travelling less.

 

Sustainability

The drive to Net Zero represents many opportunities for our business as our products positively contribute to our customers' own sustainability ambitions by reducing energy consumption, minimising waste and improving the inherent performance of the products that they supply to their customers.

 

During the period we have continued to make strong progress towards our target of Net Zero for Scopes 1 and 2 emissions by 2028, including switching to renewable energy contracts for all UK sites and our main sites in India and the US. We are also moving to ultra-low emission vehicles (ULEV) fleet vehicles in the UK and, as part of our commitment to reduce Scope 3 emissions, we have also introduced a ULEV salary sacrifice scheme, initially in the UK, which will enable our employees to reduce their commuting emissions. As part of this project, we have installed over 70 charging points at our New Mills HQ site which will be replicated at our other key sites in the UK.  

 

As part of our commitment to achieve a science-based Net Zero emissions target of no later than 2050 for our entire business, we will include in our next Annual Report our progress on three of the UN's Sustainable Development Goals (SDGs); SDG 8 (sustained, inclusive and sustainable economic growth), SDG 12 (sustainable consumption) and SDG 13 (urgent action to combat climate change).

 

Directors and employees

The Directors would like to thank our employees for their continuing efforts to drive our business forward. During the period we ran a global competition encouraging teams to share how they demonstrate our values: innovation, inspiration, integrity and involvement. We received entries from across the Group, from Mexico to China, and we announced the winning teams in December. Each team chose a charity which will shortly receive a £5,000 donation, including a school for blind children in India and a cancer treatment centre in Wales.

 

Outlook

The Board remains confident in our strategy to deliver sustainable, profitable growth over the medium term. Our approach of building long-term relationships with customers helps us to identify opportunities in our markets, and our agility and resources ensure we can respond to these opportunities. 

 

Our results so far this year have benefited from products released in recent years and the relationships we have been building with new customers. These relationships, new products and the expected improvement in semiconductor and electronics markets, supports our confidence for medium term growth. To support this, we are continuing to make targeted investments in our people, our production facilities, and our new product pipeline. We have a strong order book, and at this stage we expect full year revenue to be in the range of £690m to £730m. Adjusted profit before tax is expected to be in the range of £140m to £165m.

 

 

Sir David McMurtry

Will Lee

Allen Roberts

Executive Chairman

Chief Executive

Group Finance Director

 

 

 

2 February 2023

 

 


 

 

 

1 Note 12, 'Alternative performance measures', defines how revenue at constant exchange rates, adjusted profit before tax, adjusted operating profit and adjusted earnings per share are calculated.

 

 

 

Consolidated income statement

 

 

 

 

 

 

 

 

 

 

Notes

 

Unaudited

6 months to

31 December

2022

£'000

 

Unaudited

6 months to

31 December

2021

£'000

 

Audited

Year ended

30 June

2022

£'000

 

Revenue

2

347,679

325,176

671,076






Cost of sales

3

(172,442)

(153,293)

(313,527)






Gross profit


175,237

171,883

357,549






Distribution costs


(66,836)

(55,830)

(122,455)

Administrative expenses


(35,311)

(33,560)

(69,736)

UK defined benefit pension scheme past service cost


-

-

(11,695)

Losses from the fair value of financial instruments

10

(1,792)

(2,313)

(10,413)






Operating profit


71,298

80,180

143,250






Financial income

4

5,003

445

932

Financial expenses

4

(290)

(658)

(2,938)

Share of profits from associates and joint ventures


1,803

1,515

4,342






Profit before tax


77,814

81,482

145,586






Income tax expense

5

(13,746)

(12,949)

(25,235)






Profit for the period


64,068

68,533

120,351






Profit attributable to:





Equity shareholders of the parent company


64,068

68,533

120,351

Non-controlling interest


-

-

-

Profit for the period


64,068

68,533

120,351








Pence

Pence

Pence

Dividend per share arising in respect of the period

7

16.8

16.0

72.6






Earnings per share (basic and diluted)

6

88.1

94.2

165.4

 

 


Consolidated statement of comprehensive income and expense

 


Unaudited

6 months to

31 December

2022

£'000

Unaudited

6 months to

31 December

2021

£'000

Audited

Year ended

30 June

2022

£'000


 



Profit for the period

64,068

68,533

120,351


 



Other items recognised directly in equity:

 



 

 



Items that will not be reclassified to the Consolidated income statement:

 



Current tax on contributions to defined benefit pension schemes

-

827

1,653

Deferred tax on contributions to defined benefit pension schemes

-

(827)

(1,653)

Remeasurement of defined benefit pension scheme liabilities

16,127

(806)

69,078

Deferred tax on remeasurement of defined benefit pension scheme liabilities

(3,739)

73

(15,997)


 



Total for items that will not be reclassified

12,388

(733)

53,081

 

 



Items that may be reclassified to the Consolidated income statement:

 



Exchange differences in translation of overseas operations

2,960

434

12,151

Exchange differences in translation of overseas joint venture

456

(229)

118

Current tax on translation of net investments in foreign operations

(310)

(245)

(1,529)

Effective portion of changes in fair value of cash flow hedges, net of recycling

1,870

(3,256)

(28,423)

Deferred tax on effective portion of changes in fair value of cash flow hedges

(318)

607

6,155


 



Total for items that may be reclassified

4,658

(2,689)

(11,528)


 



Total other comprehensive income and expense, net of tax

17,046

(3,422)

41,553


 



Total comprehensive income and expense for the period

81,114

65,111

161,904

 




Attributable to:




Equity shareholders of the parent company

81,114

65,111

161,904

Non-controlling interest

-

-

-





Total comprehensive income and expense for the period

81,114

65,111

161,904

 

 


Consolidated balance sheet


 

 

 

Notes

Unaudited

At 31 December

2022

£'000

Unaudited

At 31 December

2021

£'000

Audited

At 30 June

2022

£'000

Assets





Property, plant and equipment

8

254,640

248,098

243,853

Right-of-use assets


9,321

11,973

9,950

Investment properties


10,374

-

10,568

Intangible assets

9

46,117

44,917

44,218

Investments in associates and joint ventures


21,905

17,920

20,570

Finance lease receivables

 

6,223

6,814

6,961

Employee benefits

 

61,788

-

43,241

Deferred tax assets

 

22,786

21,150

22,893

Derivatives

10

3,542

6,836

-

Total non-current assets


436,696

357,708

402,254






Current assets





Inventories


179,754

135,895

162,482

Trade receivables

10

123,141

111,864

127,551

Finance lease receivables


3,125

1,524

3,348

Contract assets


1,455

757

578

Short-term loans to associates and joint ventures


155

616

302

Current tax


7,382

3,279

8,901

Other receivables


31,929

27,174

27,068

Derivatives

10

3,948

9,839

7,121

Pension scheme cash escrow account


-

10,580

-

Bank deposits


155,541

160,000

100,000

Cash and cash equivalents


55,957

62,038

153,162

Total current assets


562,387

523,566

590,513






Current liabilities





Trade payables


21,434

27,954

30,947

Contract liabilities


8,298

5,707

12,956

Current tax


5,989

6,700

10,078

Provisions


3,513

6,342

4,244

Derivatives

10

16,149

3,877

17,890

Lease liabilities


3,535

3,644

3,714

Borrowings


959

972

919

Other payables


41,873

47,732

51,949

Total current liabilities


101,750

102,928

132,697

Net current assets


460,637

420,638

457,816






Non-current liabilities





Lease liabilities


6,068

8,672

6,466

Borrowings


4,933

5,919

5,160

Employee benefits


328

20,229

996

Deferred tax liabilities


26,952

12,029

22,815

Derivatives

10

5,933

1,598

9,463

Total non-current liabilities


44,214

48,447

44,900

Total assets less total liabilities


853,119

729,899

815,170






Equity





Share capital


14,558

14,558

14,558

Share premium


42

42

42

Own shares held


(2,963)

(750)

(750)

Currency translation reserve


17,565

3,679

14,459

Cash flow hedging reserve


(9,371)

8,696

(10,923)

Retained earnings


833,807

704,553

798,541

Other reserve


58

(302)

(180)

Equity attributable to the shareholders of the parent company


853,696

730,476

815,747

Non-controlling interest


(577)

(577)

(577)

Total equity


853,119

729,899

815,170

 

 

 

 

Consolidated statement of changes in equity

 

Unaudited

 

Share

capital

£'000

 

Share

premium

£'000

 

Own

shares

held

£'000

Currency

translation

reserve

£'000

Cash flow

hedging

reserve

£'000

 

Retained

earnings

£'000

 

Other

reserve

£'000

Non-

controlling

interest

£'000

 

 

 

Total

£'000

 

Balance at 1 July 2021

14,558

42

(404)

3,719

11,345

674,603

44

(577)

703,330











Profit for the period

-

-

-

-

-

68,533

-

-

68,533











Other comprehensive income and expense (net of tax)










Remeasurement of defined benefit pension liabilities

-

-

-

-

-

(733)

-

-

(733)

Foreign exchange translation differences

-

-

-

189

-

-

-

-

189

Relating to associates and joint ventures

-

-

-

(229)

-

-

-

-

(229)

Changes in fair value of cash flow hedges

-

-

-

-

(2,649)

-

-

-

(2,649)

Total other comprehensive income and expense

-

-

-

(40)

(2,649)

(733)

-

-

(3,422)

Total comprehensive income and expense

-

-

-

(40)

(2,649)

67,800

-

-

65,111











Transactions with owners recorded in equity










Share-based payments charge

-

-

-

-

-

-

58

-

58

Own shares transferred on vesting

-

-

404

-

-

-

(404)

-

-

Own shares purchased

-

-

(750)

-

-

-

-


(750)

Dividends paid

-

-

-

-

-

(37,850)

-

-

(37,850)

Balance at 31 December 2021

14,558

42

(750)

3,679

8,696

704,553

(302)

(577)

729,899











Profit for the period

-

-

-

-

-

51,818

-

-

51,818











Other comprehensive income and expense (net of tax)










Remeasurement of defined benefit pension liabilities

-

-

-

-

-

53,814

-

-

53,814

Foreign exchange translation differences

-

-

-

10,433

-

-

-

-

10,433

Relating to associates and joint ventures

-

-

-

347

-

-

-

-

347

Changes in fair value of cash flow hedges

-

-

-

-

(19,619)

-

-

-

(19,619)

Total other comprehensive income and expense

-

-

-

10,780

(19,619)

53,814

-

-

44,975

Total comprehensive income and expense

-

-

-

10,780

(19,619)

105,632

-

-

96,793











Transactions with owners recorded in equity










Share-based payments charge

-

-

-

-

-

-

122

-

122

Dividends paid

-

-

-

-

-

(11,644)

-

-

(11,644)

Balance at 30 June 2022

14,558

42

(750)

14,459

(10,923)

798,541

(180)

(577)

815,170


 

 

 

 

 

 

 

 

 

Profit for the period

-

-

-

-

-

64,068

-

-

64,068











Other comprehensive income and expense (net of tax)










Remeasurement of defined benefit pension liabilities

-

-

-

-

-

12,388

-

-

12,388

Foreign exchange translation differences

-

-

-

2,650

-

-

-

-

2,650

Relating to associates and joint ventures

-

-

-

456

-

-

-

-

456

Changes in fair value of cash flow hedges

-

-

-

-

1,552

-

-

-

1,552

Total other comprehensive income and expense

-

-

-

3,106

1,552

12,388

-

-

17,046

Total comprehensive income and expense

-

-

-

3,106

1,552

76,456

-

-

81,114











Transactions with owners recorded in equity










Share-based payments charge

-

-

-

-

-

-

238

-

238

Own shares purchased

-

-

(2,213)

-

-

-

-

-

(2,213)

Dividends paid

-

-

-

-

-

(41,190)

-

-

(41,190)

Balance at 31 December 2022

14,558

42

(2,963)

17,565

(9,371)

833,807

58

(577)

853,119

 

 

 

Consolidated statement of cash flow


Unaudited

6 months to

31 December

2022

£'000

Unaudited

6 months to

31 December

2021

£'000

Audited

Year ended

30 June

2022

£'000

Cash flows from operating activities




Profit for the period

64,068

68,533

120,351

Adjustments for:

 



Depreciation of property, plant and equipment, and investment properties

8,741

9,748

25,898

Loss on sale of property, plant and equipment

302

17

157

Impairment of property, plant and equipment

-

-

1,259

Depreciation of right-of-use assets

1,974

1,981

4,205

Impairment of right-of-use-assets

-

-

1,837

Amortisation of development costs

2,527

4,035

4,698

Amortisation of other intangibles

581

396

1,225

Impairment of development costs

-

185

-

Write-off of intangible assets

-

-

3,510

Share of profits from associates and joint ventures

(1,803)

(1,515)

(4,342)

Profit on disposal of investment in associate

-

-

(582)

Derecognition of lease liabilities

-

-

(1,985)

UK defined benefit pension scheme past service cost

-

-

11,695

Financial income

(5,003)

(445)

(932)

Financial expenses

290

658

2,938

(Gains)/losses from the fair value of financial instruments

(4,350)

2,936

8,349

Share based payment expense

239

59

180

Tax expense

13,746

12,949

25,235


17,244

31,004

83,345

Increase in inventories

(17,272)

(22,332)

(48,919)

Decrease/(increase) in trade and other receivables

1,777

5,375

(11,301)

(Decrease)/increase in trade and other payables

(24,411)

(1,075)

12,288

(Decrease)/increase in provisions

(732)

83

(2,015)


(40,638)

(17,949)

(49,947)

Defined benefit pension scheme contributions

(2,260)

(4,431)

(8,866)

Income taxes paid

(16,858)

(10,366)

(23,410)

Cash flows from operating activities

21,556

66,791

121,473


 


 

Investing activities

 


 

Purchase of property, plant and equipment, and investment properties

(20,229)

(12,199)

(30,960)

Sale of property, plant and equipment

2,636

363

687

Development costs capitalised

(4,201)

(4,820)

(7,966)

Purchase of other intangibles

(609)

(784)

(929)

(Increase)/decrease in bank deposits

(55,541)

(40,000)

20,000

Interest received

2,575

261

834

Dividend received from associates and joint ventures

924

-

525

Proceeds from sale of shares in associate

-

-

582

Payments from pension scheme cash escrow account

-

-

10,578

Cash flows from investing activities

(74,445)

(57,179)

(6,649)


 


 

Financing activities

 


 

Repayment of borrowings

(494)

(471)

(974)

Interest paid

(274)

(324)

(591)

Repayment of principal of lease liabilities

(2,100)

(1,741)

(4,081)

Own shares purchased

(2,212)

(750)

(750)

Dividends paid

(41,190)

(37,845)

(49,494)

Cash flows from financing activities

(46,270)

(41,131)

(55,890)


 


 

Net (decrease)/increase in cash and cash equivalents

(99,159)

(31,519)

58,934

Cash and cash equivalents at the beginning of the period

153,162

95,008

95,008

Effect of exchange rate fluctuations on cash held

1,954

(1,451)

(780)

Cash and cash equivalents at the end of the period

55,957

62,038

153,162

 

 

 

 

 

Notes

 

1.         Basis of preparation

 

The Interim report, which includes the condensed consolidated financial statements for the six months ended 31 December 2022, was approved by the Directors on 2 February 2023.

The condensed consolidated financial statements for the six months ended 31 December 2022 were prepared in accordance with International Accounting Standard 34 'Interim Financial Reporting' (IAS 34) as issued by the International Accounting Standards Board and as adopted by the UK. These apply the same accounting policies, presentation and methods of calculation as were applied in the preparation of the Group's consolidated financial statements for the year ended 30 June 2022, except for income taxes which are accrued using the forecast tax rate for the financial year, and except for the adoption of new accounting standards.

The condensed consolidated financial statements included in this Report have not been audited and do not constitute the Group's statutory accounts as defined in section 434 of the Companies Act 2006. The information relating to the year ended 30 June 2022 is an extract from the Group's published Annual Report for that year, which has been delivered to the Registrar of Companies, and on which the auditor's report was unqualified and did not contain any emphasis of matter or statements under section 498(2) or 498(3) of the Companies Act 2006.

Going concern

The Directors have prepared the unaudited interim financial information on a going concern basis. In considering the going concern basis, the Directors have considered the previously mentioned principal risks and uncertainties, as well as the Group's current trading performance and updated cashflow forecasts. The Directors have also considered the financial resources available to the Group, with net current assets of £460.6m at 31 December 2022 (compared to £457.8m at 30 June 2022), including £211.5m net cash and bank deposits at 31 December 2022.

We have updated our reverse stress testing to identify what would need to happen in the period to 31 January 2024 to result in the Group having negative bank deposit and cash balances. We found that this would occur if revenue fell to £24m, for each of the 12 months to January 2024. The £24m per month is before consideration of longer-term mitigating actions such as reducing labour costs and reducing capital expenditure, and is considerably lower than forecast. This assessment reflects the conclusion that the overall impact and likelihood of our principal risks is not considered to have changed significantly during the period.

Having made appropriate enquiries, the Directors are satisfied that, at the time of approving the unaudited condensed consolidated financial statements, it is appropriate to continue to adopt a going concern basis of accounting.

 

2.         Segmental information

 

The Group manages its business in two segments, comprising Manufacturing technologies and Analytical instruments and medical devices. Within the operating segments, there are multiple product offerings with similar economic characteristics, similar production processes and similar customer bases. The results of these segments are regularly reviewed by the Board to allocate resources and to assess their performance. More details of the Group's products and services are given in the Strategic Report of the 2022 Annual Report.

In normal trading conditions, whilst future revenue is difficult to predict given that the Group's outstanding order book is typically less than three months' worth of revenue value, larger consumer electronics orders in the APAC region within the manufacturing technologies segment typically fall in the first or last quarter of the financial year. In addition, the Group typically experiences lower demand in August and December, and so revenue and operating profits are typically lower in the first half of the year. This information is provided to allow for a better understanding of the results, and management do not believe that the business is 'highly seasonal' in accordance with IAS 34.

 

6 months to 31 December 2022

 

Manufacturing technologies

Analytical instruments and medical devices

 

 

Total

 

£'000

£'000

£'000

Revenue

330,916

16,763

347,679


 

 

 

Depreciation, amortisation and impairment

12,841

982

13,823


 

 

 

Operating profit before gains from fair value of financial instruments

72,957

133

73,090

Share of profits from associates and joint ventures

-

-

1,803

Net financial income

-

-

4,713

Losses from the fair value of financial instruments

-

-

(1,792)

Profit before tax

-

-

77,814


6 months to 31 December 2021




Revenue

308,707

16,469

325,176





Depreciation, amortisation and impairment

15,508

837

16,345





Operating profit before gains from fair value of financial instruments

80,938

1,555

82,493

Share of profits from associates and joint ventures

1,515

-

1,515

Net financial expense

-

-

(213)

Losses from the fair value of financial instruments

-

-

(2,313)

Profit before tax

-

-

81,482





Year ended 30 June 2022




Revenue

634,588

36,488

671,076





Depreciation, amortisation and impairment

36,552

2,570

39,122





Operating profit before losses from fair value of financial instruments

162,549

2,809

165,358

Share of profits from associates and joint ventures

4,342

-

4,342

Net financial expense

-

-

(2,006)

UK defined benefit pension scheme past service cost

-

-

(11,695)

Losses from the fair value of financial instruments

-

-

(10,413)

Profit before tax

-

-

145,586

 

There is no allocation of assets and liabilities to operating segments. Depreciation is included within certain other overhead expenditure which is allocated to segments on the basis of the level of activity.

The following table shows the disaggregation of Group revenue by category:


6 months to

31 December

2022

£'000

Goods, capital equipment and installation

318,959

299,077

615,641

Aftermarket services

28,720

26,099

55,435

Total Group revenue

347,679

325,176

671,076

Aftermarket services include repairs, maintenance and servicing, programming, training, extended warranties, and software licences and maintenance.

The following table shows the analysis of revenue by geographical market:


6 months to

31 December

2022

£'000

APAC

161,726

160,562

317,023

UK (country of domicile)

18,942

15,485

31,536

EMEA, excluding UK

83,497

80,007

174,290

EMEA

102,439

95,492

205,826

Americas

83,514

69,122

148,227

Total Group revenue

347,679

325,176

671,076

 

Revenue in the above table has been allocated to regions based on the geographical location of the customer. Countries with individually material revenue figures in the context of the Group were:


6 months to

31 December

2022

£'000

6 months to

31 December

2021

£'000

Year ended

30 June

2022

£'000

China

81,112

80,700

152,772

USA

73,157

60,324

128,531

Japan

34,678

32,066

69,829

Germany

30,089

27,600

58,636

 

There was no revenue from transactions with a single external customer amounting to 10% or more of the Group's total revenue.

 

 

3.         Cost of sales

 

 

 

6 months to

31 December

2022

£'000

6 months to

31 December

2021

£'000

Year ended

30 June

2022

£'000


 



Production costs

126,333

115,477

234,919

Research and development expenditure

36,202

27,944

59,415

Other engineering expenditure

14,114

12,644

26,356

Gross engineering expenditure

50,316

40,588

85,771

Development expenditure capitalised (net of amortisation)

(1,674)

(785)

(3,268)

Development expenditure impaired

-

185

-

Research and development tax credit

(2,533)

(2,172)

(3,895)

Total engineering costs

46,109

37,816

78,608

Total cost of sales

172,442

153,293

313,527

 

4.         Financial income and expenses

 

 

 

 

6 months to

31 December

2022

£'000

6 months to

31 December

2021

£'000

Year ended

30 June

2022

£'000

Financial income

 



Fair value gains from one-month forward currency contracts

59

-

98

Interest on pension schemes' assets

844

-

-

Currency gains

1,525

184

-

Bank interest receivable

2,575

261

834

Total financial income

5,003

445

932

Financial expenses

 



Interest on pension schemes' liabilities

16

156

306

Currency losses

-

-

1,414

Fair value losses from one-month forward currency contracts

-

178

-

Realised currency reserve losses from discontinuation of foreign operation

-

-

575

Lease interest

171

236

481

Interest payable on borrowings

52

30

52

Other interest payable

51

58

110

Total financial expenses

290

658

2,938







 

Currency gains and losses relate to revaluations of foreign currency-denominated balances using latest reporting currency exchange rates. Certain intragroup balances are classified as 'net investments in foreign operations', such that revaluations from currency movements on designated balances accumulate in the Currency translation reserve in Equity. Rolling one-month forward currency contracts are used to offset currency movements on remaining intragroup balances, with fair value gains and losses being recognised in financial income or expenses.

 

5.         Taxation

 

The income tax expense in the Consolidated income statement has been estimated at a rate of 17.7% (H1 FY2022: 15.9%), based on management's best estimate of the full year effective tax rates by geographical unit applied to half-year profits. This is comparable with the 17.3% achieved in FY2022, and includes an increase in the UK effective tax rate for the year to 20.5% from 19%, which is largely offset by a forecast increase in the patent box benefit.

 

6.         Earnings per share

 

The earnings per share for the six months ended 31 December 2022 is calculated on earnings of £64,068,000 (December 2021: £68,533,000 ) and on 72,719,565 shares (December 2021: 72,774,147 shares), being the number of shares in issue during the period. This excludes 68,978 shares (December 2021: 14,396 shares) held by the Renishaw Employee Benefit Trust.

 

7.         Dividends

 

 

Dividends paid during the period were:

 

6 months to

31 December

2022

£'000

6 months to

31 December

2021

£'000

Year ended

30 June

2022

£'000


 



FY2022 final dividend paid of 56.6p per share (2021: 52.0p)

41,190

37,850

37,850

Interim dividend paid of 16.0p per share (2022: 14.0p)

-

-

11,644

Total dividends paid during the period

41,190

37,850

49,494

 

All shareholders on the register on 10 March 2023 will be paid an interim dividend of 16.8p net per share on 11 April 2023, resulting in a dividend payable of £12,228,475.

 

8.         Property, plant and equipment

 

 

 

 

Freehold

land and

buildings

 

Plant and

equipment

 

Motor

vehicles

Assets in the

course of construction

 

 

Total

 

£'000

£'000

£'000

£'000

£'000

Cost






At 1 July 2022

217,820

263,557

7,520

7,481

496,378

Additions

1,080

1,078

710

17,363

20,231

Transfers

44

886

-

(930)

-

Disposals

(73)

(4,508)

(863)

-

(5,444)

Currency adjustment

2,066

868

37

-

2,971







At 31 December 2022

220,937

261,881

7,404

23,914

514,136







Depreciation






At 1 July 2022

43,816

202,214

6,495

-

252,525

Charge for the period

1,955

6,539

140

-

8,634

Released on disposals

-

(1,848)

(658)

-

(2,506)

Currency adjustment

278

527

38

-

843







At 31 December 2022

46,049

207,432

6,015

-

259,496







Net book value

 

 

 

 

 

At 31 December 2022

174,888

54,449

1,389

23,914

254,640

At 30 June 2022

174,004

61,343

1,025

7,481

243,853

 

Additions to assets in the course of construction of £17,363,000 (December 2021: £5,927,000 ) comprise £8,474,000 (December 2021: £1,095,000) for freehold land and buildings and £8,889,000 (December 2021: £4,832,000) for plant and equipment. At the end of the period, assets in the course of construction, not yet transferred, of £23,914,000 (December 2021: £11,602,000) comprise £9,707,000 (December 2021: £4,308,000) for freehold land and buildings and £14,207,000 (December 2021: £7,294,000) for plant and equipment.

 

9.         Intangible assets

 


 

Goodwill

 

Other intangible assets

Internally

generated

development costs

Software

licences and intellectual property

 

 

 

Total


£'000

£'000

£'000

£'000

£'000

Cost




 


At 1 July 2022

20,475

4,629

168,212

22,379

215,695

Additions

-

255

4,201

354

4,810

Disposals

-

-

-

(76)

(76)

Currency adjustment

201

10

-

43

254







At 31 December 2022

20,676

4,894

172,413

22,700

220,683





 


Amortisation




 


At 1 July 2022

9,028

2,240

139,460

20,749

171,477

Charge for the period

-

92

2,527

489

3,108

Released on disposals

-

-

-

(44)

(44)

Currency adjustment

-

(10)

-

35

25







At 31 December 2022

9,028

2,322

141,987

21,229

174,566





 


Net book value

 

 

 

 

 

At 31 December 2022

11,648

2,572

30,426

1,471

46,117

At 30 June 2022

11,447

2,389

28,752

1,630

44,218

 

As detailed in the 2022 Annual Report, the key assumption in determining the value-in-use of intangible assets are sales forecasts. Latest sales forecasts, and other factors which may impact the business plans, for relevant cash generating units have been reviewed for indicators of impairment at 31 December 2022. This includes a revision to our discount rate from 9.0% to 10.4% based on prevailing market assumptions at 31 December 2022. As a result, no impairments have been recognised in the six months to 31 December 2022 (December 2021: £185,000).

 

10.        Financial instruments

 

There is no significant difference between the fair value of financial assets and financial liabilities and their book value in the Consolidated balance sheet. All financial assets and liabilities are held at amortised cost, apart from the forward exchange contracts which are held at fair value, with changes going through the Consolidated income statement unless subject to hedge accounting. The fair values of the forward exchange contracts have been calculated by a third-party expert, discounting estimated future cash flows on the basis of market expectations of future exchange rates, representing level 2 in the IFRS 13 fair value hierarchy. There were no transfers between levels during any period disclosed.

 

Credit risk

The Group carries a credit risk relating to non-payment of trade receivables by its customers and establishes an allowance for impairment in respect of trade receivables where recoverability is considered doubtful. In the six months to 31 December 2022, the Group has not experienced a deterioration in debtor repayments nor in the assumptions used in calculating allowances for expected credit losses. At 31 December 2022, total expected credit losses amounted to £2,441,000, being 1.9% of gross trade receivables, compared with £2,540,000 at 30 June 2022, being 2.0% of gross trade receivables.

 

Liquidity risk

The Group's approach to managing liquidity is to ensure, as far as possible, that it will always have sufficient liquidity to meet its liabilities when due, and the Group continues to use monthly cash flow forecasts on a rolling 12-month basis to monitor cash requirements. Net cash and bank deposits at 31 December 2022 totalled £211,498,000, compared with £253,162,000 at 30 June 2022. This reduction included a dividend payment of £41,193,000 and cash generation from operating activies of £21,556,000 during the period. In consideration of this, the Group remains in a strong liquidity position.

 

Market risk

At 31 December 2022 the total nominal value of USD, EUR and JPY forward contracts held for cash flow hedging purposes was £525,603,000 (December 2021: £516,547,000). At 31 December 2022 the remaining nominal value of USD, EUR and JPY forward contracts ineffective for cash flow hedging and yet to mature amounted to £21,950,000 (December 2021: £109,199,000), with no additional forward contracts becoming ineffective for hedge accounting purposes in the six months to 31 December 2022. A decrease of 10% in the highly probable revenue forecasts of Renishaw plc and Renishaw UK Sales Limited, being the hedged item, would result in an additional £5.8m of forward contracts becoming ineffective at 31 December 2022. On an ongoing basis, a 10% depreciation of GBP against USD, EUR and JPY would result in a £2,439,000 gain being recognised in the Consolidated Income Statement, while a 10% appreciation would result in a £1,995,000 loss. Fair value gains and losses relating to this have been excluded from adjusted profit measures, see note 12 for further detail.

 

11.        Employee benefits

 

The net surplus of the Group's defined benefit pension schemes, on an IAS 19 basis, has increased from a £42,245,000 net asset at 30 June 2022 to a £61,460,000 net asset at 31 December 2022. This mostly relates to a reduction in liabilities resulting from a 1.05% increase in the UK scheme discount rate. Changes to other key assumptions from 30 June 2022 to 31 December 2022 have not had a material effect on these financial statements. During the first half of this financial year, there has also been a change in the UK scheme asset portfolio, to increase the proportion of assets held as gilts and therefore increase the correlation with future liability exposure.

 

12.        Alternative performance measures

 

In accordance with Renishaw's Alternative Performance Measures (APMs) policy and ESMA Guidelines on Alternative Performance Measures (2015), APMs are defined as - Revenue at constant exchange rates, Adjusted profit before tax, Adjusted earnings per share and Adjusted operating profit.

 

Revenue at constant exchange rates is defined as revenue recalculated using the same rates as were applicable to the previous year and excluding forward contract gains and losses.

Revenue at constant exchange rates

 

 

6 months to 31 December 2022

6 months to 31 December 2021

 

 

£'000

£'000

 

 

 


Statutory revenue as reported

 

347,679

325,176

Adjustment for forward contract losses

 

7,045

391

Adjustment to restate at previous year exchange rates

 

(26,239)

-

Revenue at constant exchange rates

 

328,485

325,567

Year-on-year revenue growth at constant exchange rates

 

1%

-

 

Adjusted profit before tax, Adjusted earnings per share and Adjusted operating profit are defined as the profit before tax, earnings per share and operating profit after excluding costs relating to business restructuring, third-party costs relating to the formal sales process ('FSP'), and gains and losses in fair value from forward currency contracts which did not qualify for hedge accounting and which have yet to mature.

 

From FY2017, the gains and losses from the fair value of financial instruments not effective for cash flow hedging have been excluded from statutory profit before tax, statutory earnings per share and statutory operating profit in arriving at Adjusted profit before tax, Adjusted earnings per share and Adjusted operating profit, to reflect the Board's intent that the instruments would provide effective hedges. This is classified as 'Fair value (gains)/losses on financial instruments not eligible for hedge accounting (i)' in the following reconciliations. The amounts shown as reported in revenue represent the amount by which revenue would change had all the derivatives qualified as eligible for hedge accounting. Gains and losses which recycle through the Consolidated income statement as a result of contracts deemed ineffective during FY2020 are also excluded from adjusted profit measures, on the basis that all forward contracts are still expected to be effective hedges for Group revenue, while the potentially high volatility in fair value gains and losses relating to these contracts will otherwise cause confusion for users of the financial statements wishing to understand the underlying trading performance of the Group. This is classified as 'Fair value (gains)/losses on financial instruments not eligible for hedge accounting (ii)' in the following reconciliations.

 

The Board considers these alternative performance measures to be more relevant and reliable in evaluating the Group's performance.

 

Adjusted profit before tax

 

6 months to 31 December 2022

6 months to  31 December 2021

Year ended    30 June      2022

 

£'000

£'000

£'000

 

 



Statutory profit before tax

77,814

81,482

145,586

Revised estimate of FY2020 restructuring provisions

-

-

(1,688)

Third-party FSP costs

-

(200)

(200)

UK defined benefit pension scheme past service cost

-

-

11,695

Fair value (gains)/losses on financial instruments not eligible for hedge accounting (i)

 



  - reported in revenue

-

2,621

2,621

  - reported in (gains)/losses from the fair value of financial instruments - derivatives

-

(1,138)

(1,138)

Fair value (gains)/losses on financial instruments not eligible for hedge accounting (ii)

 



  - reported in revenue

(6,142)

(1,998)

(4,685)

  - reported in (gains)/losses from the fair value of financial instruments - derivatives

1,792

3,451

11,551

Adjusted profit before tax

73,464

84,218

163,742

 

Adjusted earnings per share

 

6 months to 31 December 2022

6 months to 31 December 2021

Year ended 30 June 2022

 

pence

pence

pence

Statutory earnings per share

88.1

94.2

165.4

Revised estimate of FY2020 restructuring provisions

-

-

(0.3)

Third-party FSP costs

-

(0.2)

(1.9)

UK defined benefit pension scheme past service cost

-

-

13.0

Fair value (gains)/losses on financial instruments not eligible for hedge accounting (i)

 



  - reported in revenue

-

2.9

2.9

  - reported in (gains)/losses from the fair value of financial instruments - derivatives

-

(1.3)

(1.3)

Fair value (gains)/losses on financial instruments not eligible for hedge accounting (ii)

 



  - reported in revenue

(6.7)

(2.2)

(5.2)

  - reported in (gains)/losses from the fair value of financial instruments - derivatives

2.0

3.8

12.9

Adjusted earnings per share

83.4

97.2

185.5

 

Adjusted operating profit

 

6 months to 31 December 2022

6 months to

31 December 2021

Year ended 30 June 2022

 

£'000

£'000

£'000

Statutory operating profit

71,298

80,180

143,250

Revised estimate of FY2020 restructuring provisions

-

-

(1,688)

Third-party FSP costs

-

(200)

(200)

UK defined benefit pension scheme past service cost

-

-

11,695

Fair value (gains)/losses on financial instruments not eligible for hedge accounting (i)

 



  - reported in revenue

-

2,621

2,621

  - reported in (gains)/losses from the fair value of financial instruments - derivatives

-

(1,138)

(1,138)

Fair value (gains)/losses on financial instruments not eligible for hedge accounting (ii)

 



  - reported in revenue

(6,142)

(1,998)

(4,685)

  - reported in (gains)/losses from the fair value of financial instruments - derivatives

1,792

3,451

11,551

Adjusted operating profit

66,948

82,916

161,406

 

Adjustments to segmental operating profit:

Manufacturing technologies

 

6 months to 31 December 2022

6 months to

31 December 2021

Year ended 30 June

2022

 

£'000

£'000

£'000

Operating profit before gain/loss from fair value of financial instruments and UK defined benefit pension scheme past service cost

72,957

80,938

162,549

Revised estimate of 2020 restructuring provisions

-

-

(1,688)

Third-party FSP costs

-

(196)

(197)

Fair value (gains)/losses on financial instruments not eligible for hedge accounting (i)

 



  - reported in revenue

-

2,572

2,576

Fair value (gains)/losses on financial instruments not eligible for hedge accounting (ii)

 



  - reported in revenue

(6,131)

(1,960)

(4,605)

Adjusted manufacturing technologies operating profit

66,826

81,354

158,635

 

Analytical instruments and medical devices

 

6 months to 31 December 2022

6 months to 31 December 2021

Year ended 30 June 2022

 

£'000

£'000

£'000

Operating profit before loss from fair value of financial instruments and UK defined benefit pension scheme past service cost

133

1,555

2,809

Third-party FSP costs

-

(4)

(3)

Fair value (gains)/losses on financial instruments not eligible for hedge accounting (i)

 



  - reported in revenue

-

49

45

Fair value gains on financial instruments not eligible for hedge accounting (ii)

 



- reported in revenue

(11)

(38)

(80)

Adjusted analytical instruments and medical devices operating profit

122

1,562

2,771

 

 

13.        Related party transactions and events subsequent to the end of the reporting period

 

Transactions between the Company and its subsidiaries, which are related parties, have been eliminated on consolidation and are not disclosed in this note. Full details of the Group's other related party relationships, transactions and balances are given in the Group's Annual Report for the year ended 30 June 2022.

 

No related party transactions have taken place in the first six months of the financial year, or events subsequent to the end of the reporting period, that have materially affected the financial position or the performance of the Group during that period.

 

14.        Responsibility statement

 

The condensed set of financial statements is the responsibility of, and has been approved by, the Directors. We confirm that to the best of our knowledge:

 

-       As required by DTR 4.2 of the Disclosure Rules and Transparency Rules, the condensed set of financial statements, which has been prepared in accordance with the applicable set of accounting standards, gives a true and fair view of the assets, liabilities, financial position and profit or loss of the Company and the undertakings included in the consolidation as a whole. The Interim report has been prepared in accordance with IAS 34, 'Interim Financial Reporting', as issued by the International Accounting Standards Board and as adopted by the UK.

 

-       The Interim report includes a fair review of the information required by:

(a) DTR 4.2.7 of the Disclosure Rules and Transparency Rules, being an indication of important events that have occurred during the first six months of the financial year and their impact on the condensed set of financial statements; and a description of the principal risks and uncertainties for the remaining six months of the year; and

(b) DTR 4.2.8 of the Disclosure Rules and Transparency Rules, being related party transactions that have taken place in the first six months of the current financial year and that have materially affected the financial position or performance of the entity during that period; and any changes in the related party transactions described in the last Annual Report that could do so.

 

 

On behalf of the Board

 

Allen Roberts FCA

Group Finance Director

2 February 2023

 

 

 

 

 

Financial calendar

2023 interim dividend record date

10 March 2023

2023 interim dividend payment date

11 April 2023

Investor day

8 June 2023

 

 

Registered office:

Renishaw plc

New Mills

Wotton-under-Edge

Gloucestershire

GL12 8JR

UK

 

Registered number: 

01106260

Telephone:

+44 1453 524524

Email:     

uk@renishaw.com

Website:                

www.renishaw.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IR UPUMCPUPWGMG
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account. AJ Bell logo

Related Charts

Renishaw PLC (RSW)

+5.00p (+0.14%)
delayed 11:05AM